Use of Fc-MBL to Detect and Monitor the Presence of PAMPs During Septic Shock

Septic Shock Clinical Trial

— Fc-MBL/PAMPs  

Official title:

Use of Fc Mannose-Binding Lectin to Detect and Monitor the Presence of Pathogen-Associated Molecular Patterns During Septic Shock

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03457038
• Other study ID #: RC31/17/0157
• Secondary ID: 2017-A01686-47
• Status: Recruiting
• Phase: N/A
• Start date: October 18, 2018
• Est. completion date: July 18, 2019

Study information

• Verified date: April 2019
• Source: University Hospital, Toulouse
• Contact: Eric Oswald, MD
• Phone: 5 67 69 04 17
• Email: oswald.e[@]chu-toulouse.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Use Mannose Binding Lectin (MBL) as a biomarker to measure levels of Pathogen- Associated Molecular Patterns (PAMP) during septic shock. This will allow evaluating interest of this biomarker to monitor and manage a septic shock. Consecutive patients admitted for sepsis in Intensive Care Unit Department will be included. This biomarker will be compared to all the parameters monitored usually for these patients in standard care.

Description:

Septic shock still represent a major cause of admission in intensive care unit, incidence of severe sepsis is increasing, even in western countries, due to aging populations and comorbidities. Definition of septic shock was revised in 2016 by a task force, which emphasizes the need for future iterations. Indeed, there are no simple clinical or biological criteria ton diagnose septic patients with high risk of shock, or to prognose its severity. C-reactive protein (CRP) and procalcitonin (PCT) are the wider biomarkers used to monitor septic patients. But they do not correlate with sepsis severity and moreover do not distinguish unequivocally between infection and noninfected systemic inflammatory response syndrome (SIRS). Each microorganism has number of PAMPs, cell wall components (lipopolysaccharide endotoxin, peptidoglycan, outer membrane vesicles), flagella, mannan… High levels of these pathogen fragments are released in the bloodstream during sepsis. They trigger release of inflammatory cytokines that drive the sepsis cascade. Mannose binding lectin plays a pivotal role in innate immunity, binding with surface sugars of wide range of pathogens and their fragments. Thus MBL promotes opsonophagocytosis and activates the lectin-complement pathway. Fc-MBL, an engineered version of MBL has been developed to capture microorganism and treat sepsis. An ELISA, using Fc-MBL was developed to measure PAMPs in whole blood during sepsis. This assay will use Fc-MBL ELISA to quantify PAMPs during septic shock, to improve diagnostic and monitoring. But also, identifying patients with high levels of PAMPs for dialysis-like sepsis therapies.

PAMP's level will be compared to clinical, biological, microbiological and therapeutic outcomes. Its sensitivity will be evaluated by its kinetic among a septic shock (defined with Sepsis-3 criteria) and by correlation with CRP (C-Reactive Protein) and PCT (Procalcitonin). Its specificity will be evaluated by comparing its levels during septic and non-septic shocks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: July 18, 2019
• Est. primary completion date: July 18, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients

• Hospitalized in Intensive Care Unit for sepsis of any etiology

• Patients with shock criteria: defined by a hypotension, hyperlactatemia, the use of vasopressive drugs.

• Patient affiliated to a social security scheme- Patient giving consent

Exclusion Criteria:

• Minor patients

• Organ transplant

• Immunosuppressive drugs, other than corticosteroids

• Patients who decline participating to the assay

• Persons placed under legal protection, guardianship

• Pregnant woman

• Subject participating in another search including a exclusion period still in progress at pre-inclusion

Related Conditions & MeSH terms

• Septic Shock
• Shock
• Shock, Septic

Intervention

Biological:
• Blood Test
Addition to the current care but during the normal follow-up visit : At the entrance to the service: search for bacterial 16S RNA in the blood Additional blood tests (4) at T6-12-18 and 36h At each visit: Sampling of an additional heparinized blood tube for the assay PAMPs. 1 time per day: Assay of CRP and PCT from samples taken in common practice J30: Assessment of the vital status of the patient

Locations

Country	Name	City	State
France	University Hospital Toulouse	Toulouse

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Toulouse	Harvard Medical School

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quantify in whole blood presence of PAMP during a septic shock,	Quantify in whole blood presence of PAMP during a septic shock, using Fc-MBL ELISA :t o improve diagnostic by distinguishing a septic shock from another shock, and stating prognosis by studying PAMP kinetic under antibiotherapy.	Follow-up during 30 days
Secondary	Compare accuracy of Fc-MBL ELISA PAMP assay to CRP and PCT during septic shock.	PAMP's level will be compared to clinical, biological, microbiological and therapeutic outcomes. Its sensitivity will be evaluated by its kinetic among a septic shock (defined with Sepsis-3 criteria) and by correlation with CRP and PCT. Its specificity will be evaluated by comparing its levels during septic and non-septic shocks.	Follow-up during 30 days
Secondary	Study PAMP's kinetic during septic shock from various origins	PAMP's level will be compared to clinical, biological, microbiological and therapeutic outcomes. Its sensitivity will be evaluated by its kinetic among a septic shock (defined with Sepsis-3 criteria) and by correlation with CRP and PCT. Its specificity will be evaluated by comparing its levels during septic and non-septic shocks.	Follow-up during 30 days
Secondary	Identify patients who could beneficiate to a dialysis-like therapy	identifying patients with high levels of PAMPs for dialysis-like sepsis therapies	Follow-up during 30 days